These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23860204)

  • 21. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
    Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
    Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
    Glaspy J; Bukowski R; Steinberg D; Taylor C; Tchekmedyian S; Vadhan-Raj S
    J Clin Oncol; 1997 Mar; 15(3):1218-34. PubMed ID: 9060566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM; Yee L; Gabrail N; Charu V; Tomita D; Rossi G; Schwartzberg L
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
    Burstein HJ; Parker LM; Keshaviah A; Doherty J; Partridge AH; Schapira L; Ryan PD; Younger J; Harris LN; Moy B; Come SE; Schumer ST; Bunnell CA; Haldoupis M; Gelman R; Winer EP
    J Clin Oncol; 2005 Nov; 23(33):8340-7. PubMed ID: 16293865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
    Möbus V; Jackisch C; Lück HJ; du Bois A; Thomssen C; Kuhn W; Nitz U; Schneeweiss A; Huober J; Harbeck N; von Minckwitz G; Runnebaum IB; Hinke A; Konecny GE; Untch M; Kurbacher C;
    Ann Oncol; 2018 Jan; 29(1):178-185. PubMed ID: 29069370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anemia and epoetin alfa in high-dose chemotherapy programs for breast cancer patients.
    Danova M; Ferrari S
    Semin Oncol; 2002 Jun; 29(3 Suppl 8):21-5. PubMed ID: 12082650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
    Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
    Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy.
    Meadowcroft AM; Gilbert CJ; Maravich-May D; Hayward SL
    Am J Health Syst Pharm; 1998 Sep; 55(18):1898-902. PubMed ID: 9784769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa.
    Debus J; Drings P; Baurecht W; Angermund R
    Radiother Oncol; 2014 Jul; 112(1):23-9. PubMed ID: 25129551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
    Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.
    Leyland-Jones B; Bondarenko I; Nemsadze G; Smirnov V; Litvin I; Kokhreidze I; Abshilava L; Janjalia M; Li R; Lakshmaiah KC; Samkharadze B; Tarasova O; Mohapatra RK; Sparyk Y; Polenkov S; Vladimirov V; Xiu L; Zhu E; Kimelblatt B; Deprince K; Safonov I; Bowers P; Vercammen E
    J Clin Oncol; 2016 Apr; 34(11):1197-207. PubMed ID: 26858335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study.
    Rades D; Tribius S; Yekebas EF; Bahrehmand R; Wildfang I; Kilic E; Muellerleile U; Gross E; Schild SE; Alberti W
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):459-65. PubMed ID: 16584851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer.
    Steensma DP; Molina R; Sloan JA; Nikcevich DA; Schaefer PL; Rowland KM; Dentchev T; Novotny PJ; Tschetter LK; Alberts SR; Hogan TF; Law A; Loprinzi CL
    J Clin Oncol; 2006 Mar; 24(7):1079-89. PubMed ID: 16505427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
    Welch RS; James RD; Wilkinson PM; Belli F; Cowan RA
    Cancer J Sci Am; 1995; 1(4):261-6. PubMed ID: 9166486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
    Witzig TE; Silberstein PT; Loprinzi CL; Sloan JA; Novotny PJ; Mailliard JA; Rowland KM; Alberts SR; Krook JE; Levitt R; Morton RF
    J Clin Oncol; 2005 Apr; 23(12):2606-17. PubMed ID: 15452187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction in transfusion requirements with early epoetin alfa treatment in pediatric patients with solid tumors: a case-control study.
    Kronberger M; Fischmeister G; Poetschger U; Gadner H; Zoubek A
    Pediatr Hematol Oncol; 2002 Mar; 19(2):95-105. PubMed ID: 11881794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.